Patents by Inventor Nicholas Ling
Nicholas Ling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124442Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.Type: ApplicationFiled: February 3, 2022Publication date: April 18, 2024Applicant: AMGEN INC.Inventors: Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Kevin Lloyd GREENMAN, Todd J. KOHN, Kexue LI, Qingyian LIU, Ana Elena MINATTI, Primali Vasundera NAVARATNE, Liping H. PETTUS, Rene RAHIMOFF, Hui-Ling WANG, Nicholas Anthony WEIRES
-
Patent number: 11944130Abstract: A vaporizer device includes various modular components. The vaporizer device includes a first subassembly. The first subassembly includes a cartridge connector that secures a vaporizer cartridge to the vaporizer device and includes at least two receptacle contacts that electrically communicate with the vaporizer cartridge. The vaporizer device includes a second subassembly. The second subassembly includes a skeleton defining a rigid tray that retains at least a power source. The vaporizer device also includes a third subassembly. The third subassembly includes a plurality of charging contacts that supply power to the power source, and an end cap that encloses an end of the vaporizer device.Type: GrantFiled: December 24, 2020Date of Patent: April 2, 2024Assignee: JUUL Labs, Inc.Inventors: Samuel C. Anderson, Wei-Ling Chang, Brandon Cheung, Steven Christensen, Joseph Chun, Joseph R. Fisher, Jr., Nicholas J. Hatton, Kevin Lomeli, James Monsees, Andrew L. Murphy, Claire O'Malley, John R. Pelochino, Hugh Pham, Vipul V. Rahane, Matthew J. Taschner, Val Valentine, Kenneth Wong
-
Publication number: 20240101570Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, such as cancer, metabolic and blood disorders. Compounds of Formula (I) have the following structure of Formula (I).Type: ApplicationFiled: November 22, 2021Publication date: March 28, 2024Inventors: Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Francesco MANONI, Primali Vasundera NAVARATNE, Liping H. PETTUS, Rene RAHIMOFF, Nuria A. TAMAYO, Mikkel VESTERGAARD, Hui-Ling WANG, Nicholas Anthony WEIRES
-
Patent number: 11934249Abstract: Methods, apparatus, systems, and articles of manufacture are disclosed. In one example, a compute device to manage energy usage and compute performance includes at least one memory, instructions, and processor circuitry. The processor circuitry executes the instructions to determine a system power mode based on first telemetry data associated with the compute device. The processor circuitry executes the instructions to provide user activity data and second telemetry data associated with the compute device to a classification system. The processor circuitry executes the instructions to configure a plurality of parameters to manage power consumption and performance of the compute device based on a classification by the classification system.Type: GrantFiled: March 31, 2022Date of Patent: March 19, 2024Assignee: Intel CorporationInventors: Zhongsheng Wang, Chris Binns, Deepak Samuel Kirubakaran, Ashraf H Wadaa, Rajshree Chabukswar, Ahmed Shams, Sze Ling Yeap, Refael Mizrahi, Nicholas Klein
-
Publication number: 20060040863Abstract: The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.Type: ApplicationFiled: August 17, 2005Publication date: February 23, 2006Applicant: Neurocrine Biosciences, Inc.Inventors: Amitabh Gaur, Nicholas Ling, Paul Conlon
-
Patent number: 6933274Abstract: The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.Type: GrantFiled: January 8, 2003Date of Patent: August 23, 2005Assignee: Neurocrine Biosciences, Inc.Inventors: Amitabh Gaur, Nicholas Ling, Paul J. Conlon
-
Publication number: 20040214775Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.Type: ApplicationFiled: April 8, 2004Publication date: October 28, 2004Applicants: Neurocrine Biosciences, Inc., Stanford University Medical CenterInventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
-
Patent number: 6740638Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.Type: GrantFiled: October 11, 2002Date of Patent: May 25, 2004Assignees: Neurocrine Biosciences, Inc., Stanford University Medical CenterInventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
-
Publication number: 20040082503Abstract: The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.Type: ApplicationFiled: January 8, 2003Publication date: April 29, 2004Applicant: Neurocrine Biosciences, Inc.Inventors: Amitabh Gaur, Nicholas Ling, Paul J. Conlon
-
Publication number: 20030114380Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.Type: ApplicationFiled: October 11, 2002Publication date: June 19, 2003Applicant: Neurocrine Biosciences, Inc.Inventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
-
Patent number: 6562942Abstract: The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues arc provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.Type: GrantFiled: June 7, 2001Date of Patent: May 13, 2003Assignee: Neurocrine Biosciences, Inc.Inventors: Amitabh Gaur, Nicholas Ling, Paul J. Conlon
-
Patent number: 6489299Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.Type: GrantFiled: November 19, 2001Date of Patent: December 3, 2002Assignees: Stanford University Medical Center, Neurocrine Biosciences, Inc.Inventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
-
Publication number: 20020086976Abstract: The present invention is directed toward peptide analogues of human myelin basic protein. The peptide analogue is at least seven amino acids long and derived from residues 86 to 99 of human myelin basic protein. The analogues are altered from the native sequence at least at positions 91, 95, or 97. Additional alterations may be made at other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating multiple sclerosis.Type: ApplicationFiled: December 11, 2001Publication date: July 4, 2002Applicant: Neurocrine Biosciences, Inc.Inventors: Nicholas Ling, Amitabh Gaur, Paul J. Conlon, Lawrence Steinman
-
Publication number: 20020058627Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.Type: ApplicationFiled: November 19, 2001Publication date: May 16, 2002Applicant: Neurocrine Biosciences, Inc.Inventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
-
Patent number: 6369033Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.Type: GrantFiled: October 20, 1997Date of Patent: April 9, 2002Assignees: Stanford University Medical Center, Neurocrine Biosciences, Inc.Inventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
-
Patent number: 6329499Abstract: The present invention is directed toward peptide analogues of human myelin basic protein. The peptide analogue is at least seven amino acids long and derived from residues 86 to 99 of human myelin basic protein. The analogues are altered from the native sequence at least at positions 91, 95, or 97. Additional alterations may be made at other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating multiple sclerosis.Type: GrantFiled: November 18, 1994Date of Patent: December 11, 2001Assignee: Neurocrine Biosciences, Inc.Inventors: Nicholas Ling, Amitabh Gaur, Paul J. Conlon, Lawrence Steinman
-
Patent number: 6197926Abstract: The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues arc provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.Type: GrantFiled: February 23, 1999Date of Patent: March 6, 2001Assignee: Neurocrine BiosciencesInventors: Amitabh Gaur, Nicholas Ling, Paul J. Conlon
-
Patent number: 5948764Abstract: The present invention is directed toward peptide analogues of human myelin basic protein for use in the treatment of multiple sclerosis. Within one aspect, peptide analogues suitable for treating multiple sclerosis are provided which are at least seven amino acids long and derived from residues 86 to 99 of human myelin basic protein. In addition, such analogues may be altered from the native sequence at positions 87, 88, 97, 98 or 99 to a D-amino acid. Additional alterations may be made at other positions. Pharmaceutical compositions containing these peptide analogues are also provided, as well as methods for treating multiple sclerosis.Type: GrantFiled: January 9, 1997Date of Patent: September 7, 1999Assignee: Neurocrine Biosciences, Inc.Inventors: Amitabh Gaur, Paul J. Conlon, Nicholas Ling
-
Patent number: 5945401Abstract: Peptides and peptide analogues of the 65 kD isoform of human glutamic acid decarboxylase are provided for use in the treatment and prevention of diabetes. Peptide analogues contain generally from one to three amino acid alterations. Peptides and analogues may be used to diagnose diabetes and detect a predisposition to diabetes.Type: GrantFiled: June 23, 1995Date of Patent: August 31, 1999Inventors: Paul J. Conlon, Nicholas Ling, Amitabh Gaur, R. David G. Leslie, Marco Londei